Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Managment of advanced prostate cancer

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 26.07.17
Views: 739

Prof Daniel Petrylak - Yale Cancer Center, New Haven, USA

Prof Petrylak talks with ecancer at NOSCM 2017 about the management and treatment of advanced prostate cancer and new drug approvals for prostate cancer. He goes on to discuss new FDA drug approvals and the benefit on survival rates for patients with prostate cancer. He continues by talking about the side effects and secondary effects of the new drugs outlined.

Prof Petrylak last spoke to ecancer at the Best of ASCO 2017 meeting in Miami about the use of abiraterone for prostate cancer.

Related videos

follow us

Breast cancer epidemiology video

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence